Latest Articles
Immunotherapy May Be Underused in Endometrial Cancer - Cancer Therapy Advisor
Immunotherapy May Be Underused in Endometrial Cancer Cancer Therapy Advisor
Published: Nov. 20, 2024, 3:15 p.m.
Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer - The Manila Times
Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer The Manila Times
Published: Nov. 5, 2024, 2:11 p.m.
The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer - Medpage Today
The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer Medpage Today
Published: July 5, 2024, 7 a.m.
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer - Medpage Today
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer Medpage Today
Published: June 18, 2024, 7 a.m.
Novel immunotherapy combination approved for endometrial cancer - European Pharmaceutical Review
Novel immunotherapy combination approved for endometrial cancer European Pharmaceutical Review
Published: June 18, 2024, 7 a.m.
Adding Immunotherapy to Chemotherapy for Endometrial Cancer - Cleveland Clinic
Adding Immunotherapy to Chemotherapy for Endometrial Cancer Cleveland Clinic
Published: June 13, 2024, 7 a.m.
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer - Cancer Health Treatment News
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer Cancer Health Treatment News
Published: April 9, 2024, 7 a.m.
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer - Oncology News Central
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer Oncology News Central
Published: March 20, 2024, 7 a.m.
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain - FiercePharma
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain FiercePharma
Published: March 18, 2024, 7 a.m.
Link copied to clipboard!